fluorouracil has been researched along with cpi 613 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alistar, AT; Buyse, ME; Luther, S; Pardee, TS; Philip, PA; Rocha Lima, CM; Van Cutsem, E | 1 |
| Clark, CJ; Erali, RA; Howerton, R; Lima, CMSR; Mangieri, CW; Pardee, T; Shen, P; Solsky, IB; Valenzuela, CD | 1 |
2 trial(s) available for fluorouracil and cpi 613
| Article | Year |
|---|---|
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Female; Fluorouracil; Follow-Up Studies; Humans; International Agencies; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Sulfides; Survival Rate | 2019 |
Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms | 2023 |